Cost-Effectiveness Metrics Payers Seek for Digital Therapeutics

Opinion
Video

Diana Brixner, PhD, FAMCP, examines the payer perspective on including Prescription Digital Therapeutics in formularies, utilizing real-world evidence as a key metric to assess the impact, cost-effectiveness, and patient benefit of these innovative digital treatments.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!
Recent Videos
1 expert in this video
1 expert in this video
Related Content
Stethoscope sitting on money | Image credit: Valeri Luzina - stock.adobe.com

Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease

Laura Joszt, MA
August 23rd 2025
Article

Read More

A gene being edited | Image credit: natali_mis - stock.adobe.com

A Single CRISPR Treatment Could Replace a Lifetime of Daily Treatment in Hereditary Angioedema

Laura Joszt, MA
August 23rd 2025
Article

Read More

GVHD wood blocks with pills | Image credit: Dzmitry - stock.adobe.com

New Chronic GVHD Treatments Show Promise, but Long-Term Outcomes Are Not Well Understood

Laura Joszt, MA
August 23rd 2025
Article

Read More

Wooden blocks spelling GVHD | Image credit: Stanislau - adobe.stock.com

GVHD Cannot Be Wholly Prevented, so Effective Treatments Are Needed, Says Dr. Daniel Wolff

Laura Joszt, MA
August 23rd 2025
Article

Read More

Screenshot of an interview with Michelle Cespedes, M.D.

Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024

Peter Wehrwein, Managing Editor;Laura Joszt, MA
August 23rd 2025
Article

Read More

Female doctor sitting with table and various health care icons | Image credit: stock.adobe.com - ImageFlow

Pulmonary Hypertension Diagnosis on Top of ILD Subsequently Increases Healthcare Use, Costs

Laura Joszt, MA
August 23rd 2025
Article

Read More

© 2025 MJH Life Sciences

All rights reserved.